Clinical Trial Results:
A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11 months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV/Hib vaccine, in study 105539 (10PN-PD-DIT-002).
Summary
|
|
EudraCT number |
2011-000943-26 |
Trial protocol |
SE NO |
Global end of trial date |
15 Jul 2011
|
Results information
|
|
Results version number |
v3(current) |
This version publication date |
13 Dec 2020
|
First version publication date |
13 Feb 2015
|
Other versions |
v1 (removed from public view) , v2 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
115375
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01358825 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l'institut 89, Rixensart, Belgium, 1330
|
||
Public contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 004 8773793718, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 004 8773793718, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Aug 2012
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Jul 2011
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Jul 2011
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to all vaccine antigens in 5-year-old children.
|
||
Protection of trial subjects |
Since the study does not involve active vaccination, serious adverse events (SAEs) related to study procedures and/or concomitant GSK medication were documented and described in detail.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
30 May 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Norway: 46
|
||
Country: Number of subjects enrolled |
Sweden: 12
|
||
Worldwide total number of subjects |
58
|
||
EEA total number of subjects |
58
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
58
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
- | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Non-randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Infanrix hexa Group | |||||||||||||||
Arm description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Infanrix Hexa
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
Subjects from Sweden previously vaccinated with 3 doses of Infanrix hexa vaccine in the primary study (NCT00307034).
|
|||||||||||||||
Arm title
|
Infanrix-IPV/Hib Group | |||||||||||||||
Arm description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Infanrix IPV/Hib
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
Subjects from Norway previously vaccinated with 3 doses of Infanrix-IPV/Hib vaccine in the primary study (NCT00307034).
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix hexa Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix-IPV/Hib Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Infanrix hexa Group
|
||
Reporting group description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034. | ||
Reporting group title |
Infanrix-IPV/Hib Group
|
||
Reporting group description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034. |
|
||||||||||||||||
End point title |
Number of seroprotected subjects against anti-diphtheria (anti-D) and anti-tetanus (anti-T). [1] | |||||||||||||||
End point description |
A seroprotected subject is a subject with anti-D/anti-T antibody concentrations greater than (≥) or equal to 0.1 international units per milliliter (IU/mL)
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
At Day 0
|
|||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Concentrations of antibodies against anti-D and anti-T [2] | ||||||||||||||||||
End point description |
|||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
At Day 0
|
||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Number of subjects with anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations ≥5 ELISA units per milliliter (EL.U/mL). [3] | ||||||||||||||||||
End point description |
Cut-off values assessed were greater than or equal to 5 ELISA units per millilitre (EL.U/mL) in the sera of subjects seronegative before vaccination.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
At Day 0
|
||||||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Concentrations of antibodies against anti-PT, anti-FHA and anti-PRN. [4] | |||||||||||||||||||||
End point description |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At Day 0
|
|||||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of seroprotected subjects against anti-hepatitis B surface antigen (anti-HBs). [5] [6] | ||||||||
End point description |
Seroprotection = anti-HBs antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Day 0
|
||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Anti-HBs concentrations assessed only in subjects primed with a HBs-containing vaccine |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Concentrations of antibodies against anti-HBs. [7] [8] | ||||||||||
End point description |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL).
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
At Day 0
|
||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Anti-HBs concentrations assessed only in subjects who previously received a HBs containing vaccine |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of seroprotected subjects against anti-polyribosyl ribitol phosphate (anti-PRP). [9] | ||||||||||||
End point description |
A seroprotected subject is a subject with anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
At Day 0
|
||||||||||||
Notes [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Concentrations of antibodies against anti-PRP. [10] | |||||||||||||||
End point description |
Concentrations are presented as geometric mean concentrations (GMCs), expressed in micrograms per millilitre (μg/mL).
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
At Day 0
|
|||||||||||||||
Notes [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects with serious adverse events (SAEs). [11] | ||||||||||||
End point description |
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
During the entire study period (up to Day 46)
|
||||||||||||
Notes [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of subjects with anti-HBs antibody concentrations ≥ 6.2 mIU/mL [12] [13] | ||||||||
End point description |
Cut-off values assessed were greater than or equal to 6.2 milliinternational units per millilitre ( mIU/mL) in the sera of subjects seronegative before vaccination.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
At Day 0
|
||||||||
Notes [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
||||||||||||||||
Adverse events information [1]
|
||||||||||||||||
Timeframe for reporting adverse events |
SAEs: during the entire study period (Day 0 to Day 46)
|
|||||||||||||||
Adverse event reporting additional description |
As no vaccine was administered during the study, no safety data other than spontaneous SAEs were collected during the study
|
|||||||||||||||
Assessment type |
Systematic | |||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||
Dictionary version |
14
|
|||||||||||||||
Reporting groups
|
||||||||||||||||
Reporting group title |
Infanrix-IPV/Hib Group
|
|||||||||||||||
Reporting group description |
Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034. | |||||||||||||||
Reporting group title |
Infanrix hexa Group
|
|||||||||||||||
Reporting group description |
Arm group description is missing. Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034. | |||||||||||||||
|
||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||
|
||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Adverse events were not collected as the study did not involve any vaccination |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |